PBM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Psyence Biomedical Ltd (PBM) is not a strong buy for a beginner, long-term investor at this time. While there is positive news sentiment and potential catalysts from government support for psychedelic drug research, the company's financial performance is extremely poor, with significant losses in net income and EPS. Additionally, technical indicators do not strongly support a buy, and there are no proprietary trading signals or significant trading trends to justify immediate action.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 71.552, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 8.598, with resistance at 14.129 and support at 3.067. Overall, the technical indicators suggest a lack of strong directional momentum.
President Trump's executive order to expedite psychedelic drug research and allocate $50 million for clinical trials has boosted investor confidence. The stock recently surged over 111% in premarket trading, reflecting optimism in the sector.
The company's financials are extremely weak, with a 632.44% drop in net income YoY and a 142.23% decline in EPS. Additionally, there are no significant insider or hedge fund trading trends, and technical indicators do not strongly support a buy.
In Q2 2026, the company reported no revenue growth (0% YoY), a significant drop in net income (-632.44% YoY), and a sharp decline in EPS (-142.23% YoY). Gross margin remains at 0%. Overall, the financial performance is poor.
No specific analyst ratings or price targets for PBM were mentioned. However, a Canaccord analyst raised the price target for a related company, AtaiBeckley, citing confidence in late-stage trials, which may indirectly reflect optimism in the sector.
